DK 004
Alternative Names: DK-004Latest Information Update: 07 Oct 2021
Price :
$50 *
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 28 Sep 2021 Preclinical trials in Osteoarthritis in China (unspecified route) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)